Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
NCT01670812
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG:
FFP+HDMP+Rituximab
Sponsor
The First Affiliated Hospital with Nanjing Medical University